After years of promise, multiplexing technology has matured from a research tool to a critical selection device, driven by several late-stage clinical programs. The integration of advanced staining reagents, digital quantification, and sophisticated controls with calibrated systems has significantly enhanced the accuracy and reproducibility of multiplexed assays. These technological advancements have revolutionized the ability to measure and analyze multiple biomarkers simultaneously, offering a powerful approach to understanding complex tumor biology and therapeutic responses.
As the field of targeted therapies continues to evolve, particularly with the rise of Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO) therapies, this evolution in multiplexing technology is poised to play a pivotal role in improving clinical trial outcomes and patient care.
By enabling more precise selection and monitoring of patient cohorts, multiplexing can:
- Facilitate the identification of ideal therapeutic candidates
- Optimize dosing regimens
- Enhance patient selection for emerging ADC and IO therapies and combinations.
This webinar will explore how these advancements in multiplexing can directly contribute to better, more personalized cancer therapies and improve the future of oncology clinical trials.
*Akoya Biosciences is now a part of Quanterix Spatial
Developing an ADC or Immunotherapy?
Our CLIA-accredited Spatial Accelerator Laboratory can fast-track your ADC and immunotherapy programs at scale. We provide multiplex spatial ADC and targeted therapeutic development with end-to-end support from panel design and development through clinical sample testing and regulatory readiness. Click below to learn more and discuss your program’s need with a spatial expert.
Related Posts
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…